Eliminating solid tumors with AI-driven, multiplex gene-edited CAR-T cells
Advancing cell therapies that break through immunosuppressive tumor barriers, enabling effective and durable cancer control
Recognitions
HUCP Innovation Fund x CBE Ventures Competition
Finalists in the 2023 Harvard Undergraduate Capital Partners Innovation Fund x Consulting, Business, the Environment Venture Competition
Nucleate Activator Program
Finalists in the 2024 Nucleate Activator Program final pitch showcase in Boston
Presidents Innovation Challenge
Semi-finalists in the 2024 Harvard iLab's President's Innovation Challenge
Finalists in the 2024 M2D2 $200k Grand Challenge
Co-founder and CEO, Aaron Edwards selected to be a Termeer Fellow, a values-driven leadership program for first time biotech founder/CEOs
Co-founder and CSO, Ryan Murray selected to be in 5050 Program, helping foster deep tech scientists/engineers become great founders.
Redefining CAR-T with a differentiated approach:
AI-driven design and multiplex gene editing for superior efficacy against solid tumors.
Our Science
AI-Driven Design
Leveraging machine learning to pinpoint optimal gene editing combinations, enhancing CAR-T cell efficacy against solid tumors.
Multiplex Gene Editing
Employing cutting-edge technology to simultaneously edit 8+ genes, setting a new standard in cell therapy engineering.
Allogeneic CAR-T
Our allogeneic CAR-T cells are engineered to maintain efficacy against immunosuppressive solid tumor microenvironment.